<DOC>
	<DOCNO>NCT02588807</DOCNO>
	<brief_summary>The purpose study evaluate safety combine phospholipid medicinal plant treatment patient amyotrophic lateral sclerosis ( ALS )</brief_summary>
	<brief_title>Food Supplement Treatment Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>This open label pilot study , patient ( n=10 ) ALS take daily nutritional supplement 8 month . After document ALS symptom history baseline , disease severity , motor muscle function assess baseline every two month ( 0 , 2 , 4 , 6 , 8 month treatment ) . Adverse event side effect assess every visit throughout experiment . In addition , level renal function , liver function electrolyte evaluate blood sample take baseline , 4 , 8 month visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Males age 18 75 year , Females &gt; 50 year 2 . Diagnosis `` probable '' `` definite '' ALS accord El Escorial revise criterion 3 . A documented history ALS symptoms 6 month prior study enrolment , 40 month . 4 . Patients capable understanding signing Informed Consent . 1 . Patients allergic seafood 2 . Patients force vital capacity &lt; 75 % 3 . Patients respiratory dependent , underwent tracheostomy , swallow . 4 . Patients cardiovascular disease 5 . Patients diabetes 6 . Patients active peptic ulcer 7 . Diagnosis neurodegenerative disease ( Parkinson disease , Alzheimer disease , etc ) . 8 . Patients suffer chronic significant disease , malignant disease disease may risk patient interfere ability interpret result . 9 . Patients sign/understand Informed Consent Form . 10 . Female patient pregnant lactate 11 . Patients receive experimental drug participate clinical trial within 1 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>